Yu Ben

Mr. Yu Ben

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
PHPan Hu
Pan Hu
YBYu Ben
Yu Ben
JLJuan Liu
Juan Liu
WZWeicheng Zheng
Weicheng Zheng
XYXiyue Yan
Xiyue Yan
WSWenyu Shi
Wenyu Shi
Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) complicated with angioimmunoblastic T-cell lymphoma (AITL) is extremely rare and typically shows an aggressive clinical course and unsatisfactory prognosis. Here, we describe the case of a 77-year-old man who was referred to the hospital because of repeated fever, night sweats, and weight loss. He was finally diagnosed with a discordant lymphoma consisting of AITL and DLBCL, with significantly different maximum standardized uptake values on positron emission tomography/computed tomography. Based on his complex illness and poor performance status, the patient received six cycles of lenalidomide combined with R-miniCHOP regimen and achieved complete remission with tolerable and controlled toxicity. He subsequently received lenalidomide maintenance therapy and achieved sustained remission. We consider the possible causes of this discordance involved AITL and EBV-positive DLBCL, and the possible mechanism of lenalidomide action in both T-cell and B-cell non-Hodgkin lymphomas. Lenalidomide-combination therapy may be a preferable choice in patients with an EBV-associated discordant lymphoma.

14 June 2024 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
HZHui Zeng
Hui Zeng
JHJie He
Jie He
HDHai‐Bo Dong
Hai‐Bo Dong
MZMin Zhou
Min Zhou
QZQian Zhang
Qian Zhang
BCBing Chen
Bing Chen
Introduction: In recent years, the correlation between CD117 antigen and the prognosis of hematological malignancies has been demonstrated. However, there is limited literature on the clinical significance of CD117 antigen in acute promyelocytic leukemia (APL). The aim of this study was to retrospectively analyze the clinical features and prognostic significance of CD117 in APL.Methods: In this study, we retrospectively investigated the clinicopathological characteristics, outcome, and prognostic impact of negative CD117 expression (CD117−) in 169 APL patients treated with all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) containing regimen.Results: The median follow‐up period was 63.0 months. CD117− was detected in 13 APL patients (7.7%). No significant differences were found in baseline characteristics between CD117+ and CD117− subgroups. However, compared to CD117+ APL, the incidence of early death (ED) was significantly higher in CD117− APL (p = 0.023). By multivariate analysis, CD117‐ was an independent adverse prognostic factor for overall survival (OS) and progression‐free survival (PFS) (p = 0.022 and p = 0.014, respectively).Conclusions: To sum up, CD117− is associated with greater risk of ED and has the statistical power to predict inferior OS and PFS, this marker may be considered to build prognostic scores for risk‐adapted therapeutic strategies in APL management.

8 March 2023 in Life
Verified
Journal Article
Open access
PDF file
XYXiyue Yan
Xiyue Yan
JLJuan Liu
Juan Liu
YBYu Ben
Yu Ben
WZWeicheng Zheng
Weicheng Zheng
PHPan Hu
Pan Hu
WSWenyu Shi
Wenyu Shi
Follicular lymphoma (FL) is a highly prevalent indolent lymphoma, and the risk of histological transformation is approximately 2–3% per year. Transformation of FL generally occurs in the same lineage (B cell lineage). Another rare form of disease progression is the transformation of neoplastic B-cells to another cell lineage such as acute myeloid leukemia (AML). The low incidence of B-myeloid transformation associated with poor prognosis hinders the establishment of model systems to identify molecular mechanisms. A 64-year-old woman was diagnosed with FL and achieved a satisfactory response after six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Approximately one month after treatment terminated, the disease progressed to AML with an increased white blood cell count and abnormal coagulation. Interestingly, nucleotide sequence analysis of the genomic region encoding the immunoglobulin heavy-chain variable domain showed the possibility of homologous transformation from lymphoma to leukemia cells. Although the patient experienced transient improvement after undergoing treatment with one cycle of idarubicin and cytarabine combined with etoposide, she relapsed and died 8 days after venetoclax salvage therapy. Patient with B-myeloid transformation was associated with an aggressive clinical course and poor prognosis. Conventional strategies for treating histologically transformed AML were ineffective. However, treatment with a Bcl-2 inhibitor could serve as an option. Here we review the literature relevant to this rare histological transformation of FL.